Primary neuroendocrine neoplasms of the vulva: A review of the MITO rare cancer group

Amelia Barcellini & Innocenza Palaia et al. · 2023-11-17

4Citations
1Influential
Gynecological neuroendocrine neoplasms are rare entities and can be divided into two groups: carcinoids and neuroendocrine carcinomas. Due to their rarity their management is not standardized. The aim of this work is to summarize and discuss the current literature evidence on this pathology. A scoping literature review was performed in multiple databases. Thirty-one studies were included: 30 case reports and one case series. Patients' age ranged between 28 and 92 years. Surgery was the most used treatment and the surgical approach included local excision (N = 16/31; 51.6%) with (N = 5/16; 31.25%) or without (N = 11/16; 68.75%) inguinal lymphadenectomy. Adjuvant radiotherapy was delivered in 12 (38.7%) cases; instead, platinum-based therapies were frequently used when chemotherapy was chosen for adjuvant treatment. The overall survival ranged between 20 days to 4 years. However, further research is needed; currently, multimodal approach including surgery, chemotherapy and radiotherapy appeared safe and feasible for the treatment of these rare and aggressive diseases.
TL;DR

Currently, multimodal approach including surgery, chemotherapy and radiotherapy appeared safe and feasible for the treatment of these rare and aggressive diseases.

AI-generated by Semantic Scholar

Authors
Amelia Barcellini, Tullio Golia D’Augè, Vincenzo Dario Mandato, Ilaria Cuccu, Angela Musella, Robert Fruscio, Maria Giuseppa Vitale, Ruby Martinello, Giorgia Mangili, Sandro Pignata, Innocenza Palaia